Evidence-based guidelines of the spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites (nails, scalp, palms, and soles)

Autor: M, Sánchez-Regaña, M J, Aldunce Soto, I, Belinchón Romero, M, Ribera Pibernat, R F, Lafuente-Urrez, J M, Carrascosa Carrillo, C, Ferrándiz Foraster, L, Puig Sanz, E, Daudén Tello, D, Vidal Sarró, R, Ruiz-Villaverde, E, Fonseca Capdevila, M C, Rodríguez Cerdeira, M M, Alsina Gibert, E, Herrera Acosta, S E, Marrón Moya
Rok vydání: 2013
Předmět:
Zdroj: Actas dermo-sifiliograficas. 105(10)
ISSN: 1578-2190
Popis: Psoriatic lesions affecting the scalp, nails, palms, and the soles of the feet are described as difficult-to-treat psoriasis and require specific management. Involvement of these sites often has a significant physical and emotional impact on the patient and the lesions are difficult to control with topical treatments owing to inadequate penetration of active ingredients and the poor cosmetic characteristics of the vehicles used. Consequently, when difficult-to-treat sites are involved, psoriasis can be considered severe even though the lesions are not extensive. Scant information is available about the use of biologic therapy in this setting, and published data generally comes from clinical trials of patients who also had moderate to severe extensive lesions or from small case series and isolated case reports. In this article we review the quality of the scientific evidence for the 4 biologic agents currently available in Spain (infliximab, etanercept, adalimumab, and ustekinumab) and report level i evidence for the use of biologics to treat nail psoriasis (level of recommendation A) and a somewhat lower level of evidence in the case of scalp involvement and palmoplantar psoriasis.
Databáze: OpenAIRE
Externí odkaz: